BIOGEN INC. Share-based Payment Arrangement, Expense
BIOGEN INC. (BIIB) reported Share-based Payment Arrangement, Expense of -$301.50 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2025-02-12
- BIOGEN INC. share-based payment arrangement, expense for the quarter ending 2024-12-31 was -$77.50M.
- BIOGEN INC. share-based payment arrangement, expense for the quarter ending 2024-09-30 was -$75.00M.
- BIOGEN INC. share-based payment arrangement, expense for the quarter ending 2024-06-30 was -$72.90M.
- BIOGEN INC. share-based payment arrangement, expense for the quarter ending 2024-03-31 was -$76.10M.
- BIOGEN INC. share-based payment arrangement, expense for fiscal 2024 was -$301.50M.
- BIOGEN INC. share-based payment arrangement, expense for fiscal 2023 was -$274.40M.
- BIOGEN INC. share-based payment arrangement, expense for fiscal 2022 was -$263.50M.
- BIOGEN INC. share-based payment arrangement, expense for fiscal 2021 was -$246.60M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$77.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$152.50M derived: sum of 2 quarters · filed 2025-02-12 | -$225.40M derived: sum of 3 quarters · filed 2025-02-12 | -$301.50M 10-K · filed 2025-02-12 | ||||
| 2024-09-30 | -$75.00M 10-Q · filed 2024-10-30 | -$147.90M derived: sum of 2 quarters · filed 2024-10-30 | -$224.00M 10-Q · filed 2024-10-30 | -$280.60M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2024-06-30 | -$72.90M 10-Q · filed 2024-08-01 | -$149.00M 10-Q · filed 2024-08-01 | -$205.60M derived: sum of 3 quarters · filed 2025-02-12 | -$270.40M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2024-03-31 | -$76.10M 10-Q · filed 2024-04-24 | -$132.70M derived: sum of 2 quarters · filed 2025-02-12 | -$197.50M derived: sum of 3 quarters · filed 2025-02-12 | -$271.60M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-12-31 | -$56.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$121.40M derived: sum of 2 quarters · filed 2025-02-12 | -$195.50M derived: sum of 3 quarters · filed 2025-02-12 | -$274.40M 10-K · filed 2025-02-12 | ||||
| 2023-09-30 | -$64.80M 10-Q · filed 2024-10-30 | -$138.90M derived: sum of 2 quarters · filed 2024-10-30 | -$217.80M 10-Q · filed 2024-10-30 | -$287.20M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-06-30 | -$74.10M 10-Q · filed 2024-08-01 | -$153.00M 10-Q · filed 2024-08-01 | -$222.40M derived: sum of 3 quarters · filed 2025-02-12 | -$288.10M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2023-03-31 | -$78.90M 10-Q · filed 2024-04-24 | -$148.30M derived: sum of 2 quarters · filed 2025-02-12 | -$214.00M derived: sum of 3 quarters · filed 2025-02-12 | -$272.00M derived: sum of 4 quarters · filed 2025-02-12 | ||||
| 2022-12-31 | -$69.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$135.10M derived: sum of 2 quarters · filed 2025-02-12 | -$193.10M derived: sum of 3 quarters · filed 2025-02-12 | -$263.50M 10-K · filed 2025-02-12 | ||||
| 2022-09-30 | -$65.70M 10-Q · filed 2023-11-08 | -$123.70M derived: sum of 2 quarters · filed 2023-11-08 | -$194.10M 10-Q · filed 2023-11-08 | -$254.60M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-06-30 | -$58.00M 10-Q · filed 2023-07-25 | -$128.40M 10-Q · filed 2023-07-25 | -$188.90M derived: sum of 3 quarters · filed 2024-02-14 | -$246.50M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-03-31 | -$70.40M 10-Q · filed 2023-04-25 | -$130.90M derived: sum of 2 quarters · filed 2024-02-14 | -$188.50M derived: sum of 3 quarters · filed 2024-02-14 | -$244.30M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2021-12-31 | -$60.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$118.10M derived: sum of 2 quarters · filed 2024-02-14 | -$173.90M derived: sum of 3 quarters · filed 2024-02-14 | -$246.60M 10-K · filed 2024-02-14 | ||||
| 2021-09-30 | -$57.60M 10-Q · filed 2022-10-25 | -$113.40M derived: sum of 2 quarters · filed 2022-10-25 | -$186.10M 10-Q · filed 2022-10-25 | -$236.30M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-06-30 | -$55.80M 10-Q · filed 2022-07-20 | -$128.40M 10-Q · filed 2022-07-20 | -$178.70M derived: sum of 3 quarters · filed 2023-02-15 | -$214.10M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2021-03-31 | -$72.60M 10-Q · filed 2022-05-03 | -$122.90M derived: sum of 2 quarters · filed 2023-02-15 | -$158.30M derived: sum of 3 quarters · filed 2023-02-15 | -$207.80M derived: sum of 4 quarters · filed 2023-02-15 | ||||
| 2020-12-31 | -$50.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$85.70M derived: sum of 2 quarters · filed 2023-02-15 | -$135.20M derived: sum of 3 quarters · filed 2023-02-15 | -$204.50M 10-K · filed 2023-02-15 | ||||
| 2020-09-30 | -$35.40M 10-Q · filed 2021-10-20 | -$84.90M derived: sum of 2 quarters · filed 2021-10-20 | -$154.20M 10-Q · filed 2021-10-20 | -$193.50M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-06-30 | -$49.50M 10-Q · filed 2021-07-22 | -$118.80M 10-Q · filed 2021-07-22 | -$158.10M derived: sum of 3 quarters · filed 2022-02-03 | -$205.90M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-03-31 | -$69.20M 10-Q · filed 2021-04-22 | -$108.60M derived: sum of 2 quarters · filed 2022-02-03 | -$156.40M derived: sum of 3 quarters · filed 2022-02-03 | -$211.40M derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2019-12-31 | -$39.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | -$87.20M derived: sum of 2 quarters · filed 2022-02-03 | -$142.20M derived: sum of 3 quarters · filed 2022-02-03 | -$191.20M 10-K · filed 2022-02-03 | $191.20M 10-K · filed 2020-02-06 | |||
| 2019-09-30 | -$47.80M 10-Q · filed 2020-10-21 | $47.80M 10-Q · filed 2019-10-22 | -$102.80M derived: sum of 2 quarters · filed 2020-10-21 | -$151.80M 10-Q · filed 2020-10-21 | $151.80M 10-Q · filed 2019-10-22 | -$350.50M derived: sum of 4 quarters · filed 2021-02-03 | ||
| 2019-06-30 | -$55.00M 10-Q · filed 2020-07-22 | $55.00M 10-Q · filed 2019-07-24 | -$104.00M 10-Q · filed 2020-07-22 | $104.00M 10-Q · filed 2019-07-24 | -$302.70M derived: sum of 3 quarters · filed 2021-02-03 | -$262.30M derived: sum of 4 quarters · filed 2021-02-03 | ||
| 2019-03-31 | $49.00M 10-Q · filed 2020-04-23 | -$247.70M derived: sum of 2 quarters · filed 2021-02-03 | -$207.30M derived: sum of 3 quarters · filed 2021-02-03 | -$165.90M derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2018-12-31 | -$296.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | -$256.30M derived: sum of 2 quarters · filed 2021-02-03 | -$214.90M derived: sum of 3 quarters · filed 2021-02-03 | -$168.70M 10-K · filed 2021-02-03 | $168.70M 10-K · filed 2019-02-06 | |||
| 2018-09-30 | $40.40M 10-Q · filed 2019-10-22 | $81.80M derived: sum of 2 quarters · filed 2019-10-22 | $128.00M 10-Q · filed 2019-10-22 | |||||
| 2018-06-30 | $41.40M 10-Q · filed 2019-07-24 | $87.60M 10-Q · filed 2019-07-24 | ||||||
| 2018-03-31 | $46.70M 10-Q · filed 2019-04-24 | |||||||
| 2017-12-31 | $138.10M 10-K · filed 2019-02-06 | |||||||
| 2016-12-31 | -$138.10M 10-K · filed 2020-02-06 | $169.40M 10-K · filed 2017-02-02 | ||||||
| 2015-12-31 | $183.20M 10-K · filed 2018-02-01 | |||||||
| 2014-12-31 | $165.00M 10-K · filed 2017-02-02 | $165.00M 10-K · filed 2015-02-04 | ||||||
| 2013-12-31 | $146.20M 10-K · filed 2016-02-03 | $146.21M 10-K · filed 2014-02-06 | ||||||
| 2012-12-31 | $123.96M 10-K · filed 2015-02-04 | |||||||
| 2011-12-31 | $6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $42.95M derived: sum of 2 quarters · filed 2014-02-06 | $79.05M derived: sum of 3 quarters · filed 2014-02-06 | $117.35M 10-K · filed 2014-02-06 | ||||
| 2011-09-30 | $36.60M 10-Q · filed 2011-10-28 | $72.70M derived: sum of 2 quarters · filed 2011-10-28 | $111.00M 10-Q · filed 2011-10-28 | |||||
| 2011-06-30 | $36.10M 10-Q · filed 2011-07-26 | $74.40M 10-Q · filed 2011-07-26 | ||||||
| 2010-12-31 | $26.34M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $69.14M derived: sum of 2 quarters · filed 2013-02-05 | $118.53M derived: sum of 3 quarters · filed 2013-02-05 | $171.44M 10-K · filed 2013-02-05 | ||||
| 2010-09-30 | $42.80M 10-Q · filed 2011-10-28 | $41.90M 10-Q · filed 2010-10-26 | $92.20M derived: sum of 2 quarters · filed 2011-10-28 | $145.10M 10-Q · filed 2011-10-28 | $142.60M 10-Q · filed 2010-10-26 | |||
| 2010-06-30 | $49.40M 10-Q · filed 2011-07-26 | $48.70M 10-Q · filed 2010-07-20 | $102.30M 10-Q · filed 2011-07-26 | $100.70M 10-Q · filed 2010-07-20 | ||||
| 2009-12-31 | $47.31M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $88.41M derived: sum of 2 quarters · filed 2012-02-03 | $129.51M derived: sum of 3 quarters · filed 2012-02-03 | $167.21M 10-K · filed 2012-02-03 | ||||
| 2009-09-30 | $41.10M 10-Q · filed 2010-10-26 | $82.20M derived: sum of 2 quarters · filed 2010-10-26 | $119.90M 10-Q · filed 2010-10-26 | |||||
| 2009-06-30 | $41.10M 10-Q · filed 2010-07-20 | $78.89M 10-Q · filed 2010-07-20 | ||||||
| 2008-12-31 | $153.75M 10-K · filed 2011-02-04 | |||||||
| 2007-12-31 | $128.10M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |